header logo image


Page 1,320«..1020..1,3191,3201,3211,322..1,3301,340..»

Stroke Recovery

February 27th, 2013 9:49 pm


Stroke Recovery Stroke Treatment Using Adult Stem Cells
Bryn came to Dr. David Steenblock after suffering from a stroke. After going to numerous facilities he was finally able to get help with his stroke recovery after coming to Dr. David Steenblock. Dr. Steenblock used adult stem cell treatments to help aid Bryn in his stroke recovery. Call 1-800-300-1063 for more information.

By: David Steenblock

Read the rest here:
Stroke Recovery

Read More...

Stem Cells: Molly at 31 days – Video

February 27th, 2013 9:49 pm


Stem Cells: Molly at 31 days
31 days after getting her Stem cells treatment.

By: GrandPawsAZ

More:
Stem Cells: Molly at 31 days - Video

Read More...

Stem Cell Therapy Bio1103 Group 29 AM – Video

February 27th, 2013 9:48 pm


Stem Cell Therapy Bio1103 Group 29 AM
Peyton Manning and Stem Cell Research

By: megmitchell93

Excerpt from:
Stem Cell Therapy Bio1103 Group 29 AM - Video

Read More...

Group 52AM- Stem Cell Therapy – Video

February 27th, 2013 9:48 pm


Group 52AM- Stem Cell Therapy
Group 52 (BIOL1103/11:00AM) clearly illustrates the topic of Stem Cell Therapy through a class project based on a member of their own group who is considering Stem Cell Therapy.

By: Savannah Kelley

See the original post here:
Group 52AM- Stem Cell Therapy - Video

Read More...

Age-Related Macular Degeneration and Retinal Stem Cell Therapy – Video

February 27th, 2013 9:48 pm


Age-Related Macular Degeneration and Retinal Stem Cell Therapy
The problems of AMD and its potential treatment with Retinal Stem Cell Therapy BIO 1103 at UGA

By: grayson3447

Here is the original post:
Age-Related Macular Degeneration and Retinal Stem Cell Therapy - Video

Read More...

Stem Cell Therapy Boston – New England Center for Hair Restoration – Video

February 26th, 2013 6:45 am


Stem Cell Therapy Boston - New England Center for Hair Restoration
At New England Center for Hair Restoration, our Boston area specialists are working with stem cell therapy in a research environment to discover the many ways it can assist in treating hair loss. We expect to see phenomenal results, as we have already discovered many reasons as to why stem cells can be effective as a hair loss solution. If you are interested in learning more about stem cell therapy, or any other hair loss treatments available at our Boston hair restoration center, please visit http://www.nehair.com. You may contact our hair loss center at 465 S. Washington Street North Attleborough, MA 02760 (855) 563-4247, (855) 5 NE HAIR http://www.nehair.com

By: Ryan Welter

Follow this link:
Stem Cell Therapy Boston - New England Center for Hair Restoration - Video

Read More...

"Stem Cells and Alzheimer’s" Group 1 – AM – Video

February 25th, 2013 6:51 pm


"Stem Cells and Alzheimer #39;s" Group 1 - AM
This video discusses how stem cells can potentially be used to cure the underlying causes of Alzheimer #39;s Disease.

By: Caleb Stevens

See more here:
"Stem Cells and Alzheimer's" Group 1 - AM - Video

Read More...

Dr. Walter Gaman of Executive Medicine of Texas talks about stem cells – Video

February 25th, 2013 6:51 pm


Dr. Walter Gaman of Executive Medicine of Texas talks about stem cells
http://www.emtexas.com Executive Medicine of Texas is dedicated to providing confidential medical services to busy and high-profile individuals just like you. Some of the services we offer include extensive half-day physical examinations, concierge medicine, inside-out makeovers, and athletic performance evaluations with strategy plans. Our goal is to keep you healthy and vibrant for years to come. We make a difference every day in the lives of our clients. Schedule your appointment now, so we can start making a difference for you.

By: ExecutiveMedicine1

Here is the original post:
Dr. Walter Gaman of Executive Medicine of Texas talks about stem cells - Video

Read More...

Harvesting of Stem Cells – Video

February 25th, 2013 6:51 pm


Harvesting of Stem Cells
Animated video of the process of harvesting stem cells and PRP at Newin Institute for reinjection into the scalp for hair regrowth and rejuvenation in hair loss (men and women); and skin rejuvenation of the face and neck as a natural anti-ageing alternative to laser resurfacing and dermal fillers - restore skin volume and vitality. Visit newinhairtransplant.com.au or newininstitute.com.au for more information.

By: Rhett Bosnich

Read more:
Harvesting of Stem Cells - Video

Read More...

Creation of murine excisional wound splinting model and transplantation of stem cells – Video

February 25th, 2013 6:51 pm


Creation of murine excisional wound splinting model and transplantation of stem cells
All animal experiments were performed with the approval of the Animal Ethics Committee of Tsinghua University. Splints are prepared from a silicon sheet. After anesthesia, two equal sized full-thickness wounds are created on the depilated dorsal skin of a Balb/C mouse with a biopsy punch. Stem cells are injected into the dermis around the wound. Spread an instant-bonding adhesive on one side of a splint and carefully place the splint around the wound so that the wound is centered within the splint. Secure the splint to the skin with interrupted sutures. Apply stem cells in Matrigel onto the wound bed. Cover the wounds and splints with sterile transparent dressing Tegaderm. Dress the wounds with self-adhering elastic bandage. Full protocol described in: Xusheng Wang et al. The mouse excisional wound splinting model, including applications for stem cell transplantation. Nature Protocols 8, 302--309 (2013) doi:10.1038/nprot.2013.002 dx.doi.org

By: ProtocolExchange

See the original post:
Creation of murine excisional wound splinting model and transplantation of stem cells - Video

Read More...

Philippine-based group warns on stem cell medicine

February 25th, 2013 4:48 am

Manila: A Philippine-based group has aired concern over the dangers of stem cell treatment as it warned of the possibility that materials being used for such procedures could have been extracted from hapless donors, particularly human foetuses.

Dr Leo Olarte, spokesman of the Philippine Society for Stem Cell Medicine, said they were alarmed over reports coming locally and from abroad that some stem cell materials were being taken from the unborn.

At the same time he called on the Department of Health to carefully watch stem cell treatment practitioners. The Catholic Church, he said, should unite with health practitioners and put an end to such practices.

Olarte was quoted as saying in reports that allogenic stem cells from aborted foetuses of humans were being exported to the Philippines.

Article continues below

We cannot stand by and merely watch how they exploit people in poverty just to profit while allowing others who are economically well off to benefit from this, he said.

He said there were reports that human stem cells from foetuses and female egg cells were being used in anti-ageing procedures and other medical treatments.

Olarte is also concerned over the sale of supposedly stem cell products that come in the form of injectibles and even soaps.

Dont patronise those products. An example is the stem cell soap. It is unfair that stem cell therapy becomes a quackery, he said.

Earlier, Department of Health Secretary Enrique Ona led a national convention participated in by doctors to discuss the truth behind stem cell therapy.

Read the original post:
Philippine-based group warns on stem cell medicine

Read More...

Group 62AM Alzheimer’s Stem Cell Therapy – Video

February 25th, 2013 4:47 am


Group 62AM Alzheimer #39;s Stem Cell Therapy
Group 62AM #39;s video for Biology 1103 at UGA

By: Brooke Dillard

Link:
Group 62AM Alzheimer's Stem Cell Therapy - Video

Read More...

Stem Cells for Degenerative Disc Disease – Manila Philippines – Video

February 24th, 2013 5:41 pm


Stem Cells for Degenerative Disc Disease - Manila Philippines
Degenerative Disc Disease was treated successfully at the ASCI in Manila Philippines using the patient #39;s own autologous stem cells: http://www.stem-cell-regeneration.com

By: stemcellregeneration

More here:
Stem Cells for Degenerative Disc Disease - Manila Philippines - Video

Read More...

Regenerative Properties of stem cells Prof May Hasaballa Cairo University – Video

February 24th, 2013 5:41 pm


Regenerative Properties of stem cells Prof May Hasaballa Cairo University
Regenerative Properties of stem cells Prof May Hasaballa Cairo University

By: mansvu

Read the rest here:
Regenerative Properties of stem cells Prof May Hasaballa Cairo University - Video

Read More...

BMP needed for cartilage repair and growth in arthritis – Video

February 24th, 2013 5:40 pm


BMP needed for cartilage repair and growth in arthritis
http://www.stemcellsarthritistreatment.com Bone morphogenic protein or BMP is an essential ingredient needed for normal cartilage development, growth, and repair. Mouse models deficient in this protein show significant deformities as do humans deficient in the gene responsible for BMP. BMP has been shown to stimulate cartilage growth from mesenchymal stem cells and enhance the production of collagen. However, it has also been shown that when implanted in areas away from where cartilage would normally grow, BMP led to the formation of ectopic bone, meaning bone growing in areas it shouldn #39;t. http

By: Nathan Wei

The rest is here:
BMP needed for cartilage repair and growth in arthritis - Video

Read More...

City of Hope Exec Will Leave California Stem Cell Agency Board

February 24th, 2013 3:05 am
Michael Friedman
City of Hope photo
The governing board of the $3 billion
California stem cell agency will lose another one of its veteran
members this year – Michael Friedman, the CEO of the City of Hope
in the Los Angeles area.
He will join Claire Pomeroy in leaving
the board. Pomeroy is resigning as vice chancellor of Human Health
Services at UC Davis this spring to become president of the Lasker Foundation in New York.. Friedman is retiring at the end of this year.
Both have been on the CIRM board since
its first meeting in December 2004. Pomeroy was appointed by the UC
Davis chancellor. Friedman was appointed by the state treasurer.
No names have surfaced concerning
likely successors. However, the UC Davis chancellor is required by
law to appoint an executive officer from the campus. The new dean at
the UCD medical school would seem to be the most likely candidate.
To fill Friedman's seat, Treasurer Bill
Lockyer
must appoint an executive officer from a California research
institute. The tradition on the board has been for particular
institutes to hold particular seats on the board. The major exception
is the Salk Institute, which lost a seat on the board a few years
back.
Both UC Davis and the City of Hope have
benefited enormously from CIRM largess. UC Davis has received $131
million and the City of Hope $51 million. Although Friedman and
Pomeroy have not been allowed to vote on grants to their
institutions, their presence and the presence on the board of other executives
from beneficiary institutions has triggered calls for sweeping changes at the agency.
A blue-ribbon report by the Institute
of Medicine
said “far too many” board members are linked to
institutions that receive money from CIRM. The institute recommended
that a new majority of independent members be created on the board.
According to compilations by the
California Stem Cell Report, about 90 percent of the $1.8 billion the
board has awarded has gone to institutions with ties to past and
present board members. Fifteen of the 29 members of the board, which
has no independent members along the lines suggested by the IOM, are
linked to recipient institutions.
The agency has $700 million remaining
before money for new awards runs out in less than four years.  

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/DWx8xx07ZOY/city-of-hope-exec-will-leave-california.html

Read More...

Monitoring the Cash and IP at the California Stem Cell Agency

February 24th, 2013 3:05 am

The $3 billion California stem cell
agency appears unlikely to make any changes in who gets the cash from
any commercial products that its research grants help finance despite
recommendations from the Institute of Medicine(IOM).

The subject will come up next Wednesday
during a meeting of the intellectual property subcommittee of the
governing board of the stem cell agency. Intellectual property (IP) simply
determines ownership rights and the share of any revenue from
therapies that result from research.
CIRM staff has prepared a briefing paper with recommendations for next week's meeting, which has
teleconference locations in La Jolla, Los Angeles, two in Irvine
along with the main site in San Francisco.
The document summarized two key IOM
recommendations in this fashion:

“Because CIRM is a new institution
without a track record to reassure stakeholders, and because its
finite funding timeline means as yet unknown agencies will be
enforcing these policies years down the road, CIRM should “propose
regulations that specify who will have the power and authority to
assert and enforce in the future rights retained by the state” in
CIRM IP, specifically referring to march-in rights, access plans and
revenue sharing....

“Second, as other sources of funding
become more prevalent, the agency should “reconsider whether its
goal of developing cures would be better served by harmonizing CIRM’s
IP policies wherever possible with the more familiar policies of the
BayhDole Act.

Here are the CIRM staff
recommendations.

“CIRM staff has engaged in
preliminary discussions several years ago with other agencies
regarding future enforcement of CIRM’s regulations and agreements.
Staff proposes to restart those discussions and return to the
Subcommittee (or the Board) with a formal proposal to address future
enforcement of CIRM’s IP regulations.”

“In light of the IOM’s own
recognition that it may be premature to assess whether CIRM’s
regulations will act as a deterrence to future investment, the fact
that a number of CIRM’s regulations have been codified in statutes
and CIRM’s positive progress in its industry engagement efforts to
date, although quite early, CIRM staff proposes to continue to
monitor this area and not to pursue any changes at this time.”

The director's subcommittee is unlikely
to diverge significantly from the staff proposal, which was dated
Feb. 14 but not posted on the CIRM website until Feb. 20.   

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/xvosTob7Zo0/monitoring-cash-and-ip-at-california.html

Read More...

Half-full, Half-empty Editorial on California Stem Cell Agency

February 24th, 2013 3:05 am

The California stem cell agency's
editorial road show paid off a bit again this week with a mildly
approving editorial in the Oakland Tribune.

The Feb.18 piece said that the presence
of Jonathan Thomas, a Los Angeles bond financier, as chairman of the
$3 billion agency has improved things, compared to the reign of Bob
Klein
, who “built a protective shield” around the agency's
governing board and prevented action to deal with obvious
conflict-of-interest problems.
The newspaper also said that “to some
extent” the agency has brought “cutting edge” scientists to the
state and helped boost the stem cell field.
That was the half-full side of the
editorial. The half-empty side included the headline.

“California
must get its stem cell house in order”

The editorial continued:

“...{T)he agency must prove that it
understands how to properly handle the public's money. …. If
the stem cell agency can establish a record as a good steward of
public dollars to finance brilliant science, it can continue to play
a useful role in stimulating and guiding research to bring the
potential cures from stem cell research to fruition.

“If it cannot do that, it will be
just another expensive Tyrannosaurus rex.”

Thomas and company are knocking on
editorial doors around the state in hopes of building support for the
board's modest – some might say inadequate – response to
recommendations for sweeping changes at the agency.  

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/tMt6gs55Yvs/half-full-half-empty-editorial-on.html

Read More...

Time For Public Disclosure of Financial Interests of Stem Cell Agency Reviewers

February 24th, 2013 3:05 am

Should the scientists who evaluate
and score the applications for $3 billion in taxpayer funds be
required to publicly disclose their financial interests?

No, says the California stem cell
agency, despite concerns by the state auditor and the state's Fair
Political Practices Commission (FPPC)
that date back at least six
years. The agency says that its governing board makes the decisions
on the applications – not the grant reviewers – and that the
members of the board fully disclose their economic interests.
However, last month the agency produced
a document that sheds new light on the issue. The document confirms
that the board rubber-stamps virtually all the reviewers' decisions,
going along with their actions 98 percent of the time. The board
exercised independent judgment on 28 out of 1,355 applications.
Why is this important? Here is what the state auditor said in 2007,

“(T)he FPPC believes that, under
state regulations, working group members (including grant reviewers)
may act as decision makers if they make substantive recommendations
that are, over an extended period, regularly approved without
significant amendment or modification by the committee. Thus, as
decision makers, working group members would need to be subject to
the conflict-of-interest code. This would mean that working groups
would be subject not only to the (public) financial disclosure requirements of
the Political Reform Act but also to the prohibition against a member
participating in a government decision in which that member has a
disqualifying financial interest and may be subject to the penalties
that may be imposed on individuals who violate that act.”

The auditor recommended that the stem
cell agency seek an attorney general's opinion on the matter, a
recommendation the agency agency summarily dismissed seven months later..
Then interim CIRM
President Richard Murphy, a former member of the agency's board and
former president of the Salk Institute, replied to the auditor:

"We have given careful
consideration to your recommendation and have decided it is not
appropriate to implement at this time. In almost three years of
operation and approval of four rounds of grants, the recommendations
of the CIRM working groups have never been routinely and/or regularly
adopted by the ICOC. Until the time that such a pattern is detected,
the question you suggest we raise with the attorney general is
entirely hypothetical, and is therefore not appropriate for
submission. We will, however, continue to monitor approvals for such
a pattern and will reconsider our decision if one emerges."

In the four rounds mentioned in
Murphy's response, 100 percent of reviewer decisions were
rubber-stamped by the board. In the other two rounds, the percentage
was 95 and 96 percent.
Currently, scientific grant reviewers at the stem cell agency, all of whom are from out-of-state, disclose financial and professional conflicts
of interest in private to selected CIRM officials. (See policy here.)
From time to time, grant reviewers are excused from evaluating
specific applications.
The CIRM governing board has resisted
requiring public disclosure of the interests of reviewers. The subject
has come up several times, but board members have been concerned
about losing reviewers who would not be pleased about disclosing
their financial interests.  Nonetheless, disclosure of interests among researchers is becoming routine in scientific research articles. Many universities, including
Stanford, also require public disclosure of financial interests of
their researchers. Stanford says,

“No matter what the circumstances --
if an independent observer might reasonably question whether the
individual's professional actions or decisions are determined by
considerations of personal financial gain, the relationship should be
disclosed to the public during presentations, in publications,
teaching or other public venues.”

The latest version of CIRM's conflict
of interest rules are under review by the FPPC. They do not include
any changes in public disclosure for grant reviewers. In view of the
new information that confirms that reviewers are making 98 percent of
the decisions on who gets the taxpayers' dollars, it would seem that it is long past due for public disclosure of both financial and professional
interests of reviewers. Indeed, given the nature of scientific
research and the tiny size of the stem cell community, disclosure of
professional interests may be more important than financial
disclosures.
As Francis S. Collins, head of the NIH,
said concerning his organization's own strengthening of disclosure requirements,

"The public trust in what we do is
just essential, and we cannot afford to take any chances with the
integrity of the research process."

Here is the CIRM document concerning
reviewers' decisions and governing board action. The table has not
been posted on the CIRM website, but it was prepared for last month's
meeting dealing with the Institute of Medicine's recommendations for
sweeping changes at the agency, especially related to conflicts of
interest.

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/oma-MLcANoY/time-for-public-disclosure-of-financial.html

Read More...

City of Hope Exec Will Leave California Stem Cell Agency Board

February 24th, 2013 3:02 am
Michael Friedman
City of Hope photo
The governing board of the $3 billion
California stem cell agency will lose another one of its veteran
members this year – Michael Friedman, the CEO of the City of Hope
in the Los Angeles area.
He will join Claire Pomeroy in leaving
the board. Pomeroy is resigning as vice chancellor of Human Health
Services at UC Davis this spring to become president of the Lasker Foundation in New York.. Friedman is retiring at the end of this year.
Both have been on the CIRM board since
its first meeting in December 2004. Pomeroy was appointed by the UC
Davis chancellor. Friedman was appointed by the state treasurer.
No names have surfaced concerning
likely successors. However, the UC Davis chancellor is required by
law to appoint an executive officer from the campus. The new dean at
the UCD medical school would seem to be the most likely candidate.
To fill Friedman's seat, Treasurer Bill
Lockyer
must appoint an executive officer from a California research
institute. The tradition on the board has been for particular
institutes to hold particular seats on the board. The major exception
is the Salk Institute, which lost a seat on the board a few years
back.
Both UC Davis and the City of Hope have
benefited enormously from CIRM largess. UC Davis has received $131
million and the City of Hope $51 million. Although Friedman and
Pomeroy have not been allowed to vote on grants to their
institutions, their presence and the presence on the board of other executives
from beneficiary institutions has triggered calls for sweeping changes at the agency.
A blue-ribbon report by the Institute
of Medicine
said “far too many” board members are linked to
institutions that receive money from CIRM. The institute recommended
that a new majority of independent members be created on the board.
According to compilations by the
California Stem Cell Report, about 90 percent of the $1.8 billion the
board has awarded has gone to institutions with ties to past and
present board members. Fifteen of the 29 members of the board, which
has no independent members along the lines suggested by the IOM, are
linked to recipient institutions.
The agency has $700 million remaining
before money for new awards runs out in less than four years.  

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/DWx8xx07ZOY/city-of-hope-exec-will-leave-california.html

Read More...

Page 1,320«..1020..1,3191,3201,3211,322..1,3301,340..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick